^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    trastuzumab rezetecan (SHR-A1811)

    i
    Other names: SHR-A1811, SHRA1811, SHR A1811, SHR-1811, SHR1811, SHR 1811
    Company:
    Glenmark, Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    4d
    SHR-A1811(sc)-101: A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor (clinicaltrials.gov)
    P1, N=107, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    trastuzumab rezetecan (SHR-A1811)
    6d
    TAYLOR: Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • Irene (pyrotinib) • albumin-bound paclitaxel • trastuzumab rezetecan (SHR-A1811)
    15d
    Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=249, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab) • docetaxel • albumin-bound paclitaxel • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    15d
    Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, Fudan University | Not yet recruiting --> Recruiting | N=120 --> 160
    Enrollment open • Enrollment change
    |
    trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • AiRuiLi (adebrelimab) • HRS-4642 • garetatug rezetecan (SHR-A1904)
    19d
    Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=45, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Herceptin (trastuzumab) • fulvestrant • trastuzumab rezetecan (SHR-A1811)
    21d
    SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Perjeta (pertuzumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811) • AiRuiKang (dalpiciclib)
    24d
    Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, First Hospital of China Medical University
    New P2 trial
    |
    letrozole • trastuzumab rezetecan (SHR-A1811)
    30d
    A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=400, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    1m
    A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    1m
    A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor (clinicaltrials.gov)
    P1, N=107, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1 trial
    |
    trastuzumab rezetecan (SHR-A1811)
    2ms
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
    2ms
    MA-UC-II-007: Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (clinicaltrials.gov)
    P2, N=96, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Herceptin (trastuzumab) • carboplatin • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)